Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. We are called Stro...
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. We are called Strongbridge for a reason. Our name reflects the collective strength of our rare disease expertise, our product portfolio and pipeline, and our patient-driven culture—one that is fueled by performance, precision and heart. Together, we are working to remove the barriers and isolation associated with rare neuromuscular and endocrine diseases in order to connect patients with the life-enhancing treatment options they deserve. Strongbridge is incorporated in Ireland, and its U.S. headquarters are located just outside of Philadelphia, PA. Strongbridge Biopharma is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.\\Rare Focus. Rare Commitment. Rare Passion. That's Strongbridge.
Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.
Join Apollo to reach decision makers at Strongbridge Biopharma plc